158 related articles for article (PubMed ID: 31646080)
21. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
[TBL] [Abstract][Full Text] [Related]
22. 15 kDa granulysin causes differentiation of monocytes to dendritic cells but lacks cytotoxic activity.
Clayberger C; Finn MW; Wang T; Saini R; Wilson C; Barr VA; Sabatino M; Castiello L; Stroncek D; Krensky AM
J Immunol; 2012 Jun; 188(12):6119-26. PubMed ID: 22586033
[TBL] [Abstract][Full Text] [Related]
23. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
24. Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression with progression of cancer.
Kishi A; Takamori Y; Ogawa K; Takano S; Tomita S; Tanigawa M; Niman M; Kishida T; Fujita S
Cancer Immunol Immunother; 2002 Jan; 50(11):604-14. PubMed ID: 11807624
[TBL] [Abstract][Full Text] [Related]
25. Hemolysis of erythrocytes by granulysin-derived peptides but not by granulysin.
Li Q; Dong C; Deng A; Katsumata M; Nakadai A; Kawada T; Okada S; Clayberger C; Krensky AM
Antimicrob Agents Chemother; 2005 Jan; 49(1):388-97. PubMed ID: 15616319
[TBL] [Abstract][Full Text] [Related]
26. Increased prevalence of peripheral blood granulysin-producing cytotoxic T lymphocytes in preeclampsia.
Molvarec A; Shiozaki A; Ito M; Toldi G; Stenczer B; Szarka A; Nakashima A; Vásárhelyi B; Rigó J; Saito S
J Reprod Immunol; 2011 Sep; 91(1-2):56-63. PubMed ID: 21763002
[TBL] [Abstract][Full Text] [Related]
27. NK cells use perforin rather than granulysin for anticryptococcal activity.
Ma LL; Wang CL; Neely GG; Epelman S; Krensky AM; Mody CH
J Immunol; 2004 Sep; 173(5):3357-65. PubMed ID: 15322199
[TBL] [Abstract][Full Text] [Related]
28. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
Bhatia J; Sharma SK; Chester KA; Pedley RB; Boden RW; Read DA; Boxer GM; Michael NP; Begent RH
Int J Cancer; 2000 Feb; 85(4):571-7. PubMed ID: 10699932
[TBL] [Abstract][Full Text] [Related]
29. Expression, processing and transcriptional regulation of granulysin in short-term activated human lymphocytes.
Latinovic-Golic S; Walch M; Sundstrom H; Dumrese C; Groscurth P; Ziegler U
BMC Immunol; 2007 Jun; 8():9. PubMed ID: 17596262
[TBL] [Abstract][Full Text] [Related]
30. Expression of granulysin mRNA in the human megakaryoblastic leukemia cell line CMK.
Kitamura N; Koshiba M; Horie O; Ryo R
Acta Haematol; 2002; 108(1):13-8. PubMed ID: 12145461
[TBL] [Abstract][Full Text] [Related]
31. Dimethyl 2,2-dichlorovinyl phosphate (DDVP) markedly decreases the expression of perforin, granzyme A and granulysin in human NK-92CI cell line.
Li Q; Nakadai A; Ishizaki M; Morimoto K; Ueda A; Krensky AM; Kawada T
Toxicology; 2005 Sep; 213(1-2):107-16. PubMed ID: 16002202
[TBL] [Abstract][Full Text] [Related]
32. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
[TBL] [Abstract][Full Text] [Related]
33. Biology and clinical relevance of granulysin.
Krensky AM; Clayberger C
Tissue Antigens; 2009 Mar; 73(3):193-8. PubMed ID: 19254247
[TBL] [Abstract][Full Text] [Related]
34. Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type.
Lo Bello G; Akarca AU; Ambrosio MR; Agostinelli C; Molina-Kirsch H; Ramsay A; Rodriguez-Justo M; Pugh M; Zhao S; DeLisser M; Sabattini E; Dojcinov S; Pileri SA; Natkunam Y; Leoncini L; Marafioti T
Virchows Arch; 2018 Dec; 473(6):749-757. PubMed ID: 30151671
[TBL] [Abstract][Full Text] [Related]
35. Biosynthesis of granulysin, a novel cytolytic molecule.
Hanson DA; Kaspar AA; Poulain FR; Krensky AM
Mol Immunol; 1999 May; 36(7):413-22. PubMed ID: 10449094
[TBL] [Abstract][Full Text] [Related]
36. Granulysin, a new human cytolytic granule-associated protein with possible involvement in cell-mediated cytotoxicity.
Peña SV; Krensky AM
Semin Immunol; 1997 Apr; 9(2):117-25. PubMed ID: 9194222
[TBL] [Abstract][Full Text] [Related]
37. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
38. Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment.
Girgis MD; Olafsen T; Kenanova V; McCabe KE; Wu AM; Tomlinson JS
EJNMMI Res; 2011 Nov; 1(1):24. PubMed ID: 22214289
[TBL] [Abstract][Full Text] [Related]
39. Comparison of multiple anti-CEA immunotoxins active against human adenocarcinoma cells.
Levin LV; Griffin TW; Childs LR; Davis S; Haagensen DE
Cancer Immunol Immunother; 1987; 24(3):202-6. PubMed ID: 3496151
[TBL] [Abstract][Full Text] [Related]
40. Granulysin in human serum as a marker of cell-mediated immunity.
Ogawa K; Takamori Y; Suzuki K; Nagasawa M; Takano S; Kasahara Y; Nakamura Y; Kondo S; Sugamura K; Nakamura M; Nagata K
Eur J Immunol; 2003 Jul; 33(7):1925-33. PubMed ID: 12884856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
